WallStreetZenWallStreetZen

NASDAQ: RNAZ
Transcode Therapeutics Inc Stock

$0.63-0.03 (-4.55%)
Updated Feb 3, 2023
RNAZ Price
$0.63
Fair Value Price
N/A
Market Cap
$8.12M
52 Week Low
$0.28
52 Week High
$3.08
P/E
-0.53x
P/B
0.99x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$15.23M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.46
Operating Cash Flow
-$13M
Beta
1.15
Next Earnings
Mar 30, 2023
Ex-Dividend
N/A
Next Dividend
N/A

RNAZ Overview

TransCode Therapeutics Incorporated is a biopharmaceutical company that develops drugs and diagnostics for treating and identifying metastatic disease. The company's lead therapeutic candidate is TTX-MC138, a preclinical stage product for the treatment of metastatic cancer. TransCode Therapeutics was incorporated in 2016 and is headquartered in Boston, MA.

Zen Score

Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how RNAZ scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

RNAZ is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
RNAZ is good value based on its book value relative to its share price (0.99x), compared to the US Biotechnology industry average (5.11x)
P/B vs Industry Valuation
RNAZ is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more RNAZ due diligence checks available for Premium users.

Be the first to know about important RNAZ news, forecast changes, insider trades & much more!

RNAZ News

Valuation

RNAZ fair value

Fair Value of RNAZ stock based on Discounted Cash Flow (DCF)
Price
$0.63
Fair Value
$1.24
Undervalued by
49.09%
RNAZ is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

RNAZ price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.53x
Industry
10.7x
Market
15.09x

RNAZ price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.99x
Industry
5.11x
RNAZ is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

RNAZ's financial health

Profit margin

Revenue
$0.0
Net Income
-$4.3M
Profit Margin
0%
RNAZ's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$12.0M
Liabilities
$3.8M
Debt to equity
0.46
RNAZ's short-term assets ($11.57M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RNAZ's short-term assets ($11.57M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RNAZ's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$4.4M
Investing
$0.0
Financing
-$225.8k
RNAZ's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

RNAZ vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
RNAZ$8.12M-5.15%-0.53x0.99x
SNPX$8.15M0.00%-0.58x0.31x
NBSE$7.99M+1.68%-0.23x0.34x
UNCY$7.97M+3.53%-0.52x1.72x
CWBR$7.94M-4.55%-0.71x0.42x

Transcode Therapeutics Stock FAQ

What is Transcode Therapeutics's quote symbol?

NASDAQ: RNAZ) Transcode Therapeutics trades on the NASDAQ under the ticker symbol RNAZ. Transcode Therapeutics stock quotes can also be displayed as NASDAQ: RNAZ.

If you're new to stock investing, here's how to buy Transcode Therapeutics stock.

What is the 52 week high and low for Transcode Therapeutics (NASDAQ: RNAZ)?

(NASDAQ: RNAZ) Transcode Therapeutics's 52-week high was $3.08, and its 52-week low was $0.28. It is currently -79.68% from its 52-week high and 122.78% from its 52-week low.

How much is Transcode Therapeutics stock worth today?

(NASDAQ: RNAZ) Transcode Therapeutics currently has 12,977,234 outstanding shares. With Transcode Therapeutics stock trading at $0.63 per share, the total value of Transcode Therapeutics stock (market capitalization) is $8.12M.

Transcode Therapeutics stock was originally listed at a price of $5.29 in Jul 9, 2021. If you had invested in Transcode Therapeutics stock at $5.29, your return over the last 1 years would have been -88.17%, for an annualized return of -88.17% (not including any dividends or dividend reinvestments).

How much is Transcode Therapeutics's stock price per share?

(NASDAQ: RNAZ) Transcode Therapeutics stock price per share is $0.63 today (as of Feb 3, 2023).

What is Transcode Therapeutics's Market Cap?

(NASDAQ: RNAZ) Transcode Therapeutics's market cap is $8.12M, as of Feb 6, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Transcode Therapeutics's market cap is calculated by multiplying RNAZ's current stock price of $0.63 by RNAZ's total outstanding shares of 12,977,234.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.